Application of formononetin to treatment of nonalcoholic fatty liver disease

A formononetin, non-alcoholic technology, applied in the application field of formononetin in the treatment of non-alcoholic fatty liver, can solve the problem of not having formononetin and the like, and achieve the improvement of lipid metabolism disorder , improve insulin resistance

Inactive Publication Date: 2019-08-06
CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no relevant report on the use of formononetin in the research and treatment of non-alcoholic fatty liver disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of formononetin to treatment of nonalcoholic fatty liver disease
  • Application of formononetin to treatment of nonalcoholic fatty liver disease
  • Application of formononetin to treatment of nonalcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1: In vivo animal model experiments

[0058] 1. Preparation of high-fat diet (HFD) diet-induced non-alcoholic fatty liver model in mice

[0059] 1.1 Test grouping

[0060] The present invention adopts the method of giving high-fat diet (HFD) to C57BL / 6 mice for 16 weeks to establish a non-alcoholic fatty liver animal model, and verifies its curative effect by intragastric administration of FMN;

[0061] Specific process: The mice were fed with a high-fat diet (HFD), and the fat in the HFD provided 60% of the total calories of the diet. HFD-induced fatty liver is recognized as one of the classic models of NAFLD. Rodents fed HFD for a long time (more than 2 months) will naturally develop hepatic steatosis, and simultaneously develop obesity, hyperlipidemia, and insulin resistance. Inflammation and fibrosis occur less frequently. Select 24 C57BL / 6J male mice, after 7 days of adaptive feeding, they were randomized into normal feeding (ND) group, normal feeding+f...

Embodiment 2

[0087] Embodiment 2: In vitro cell model experiments

[0088] 1) Select the HepG2 liver cancer cell line and primary isolated mouse hepatocytes, stimulate HepG2 cells and primary mouse hepatocytes with 1 mM FFAs for 24 hours, and successfully establish the cell steatosis model, then inject formononetin (20μM ) for 24 h, and at the same time set the BSA group (HepG2 cells were cultured in DMEM low-glucose medium containing 1 % BSA without fetal bovine serum). After the drug intervention, the cells and cell proteins were collected, and the changes in the contents of TG and lipid droplets in the cells were detected later.

[0089] 2) Lipid droplet staining: (1) Cell synchronization: Inoculate HepG2 cells and primary mouse hepatocytes in a 96-well plate (2×103 / well); culture at 37°C, 5% CO2 for 24 h, replace with DMEM Low-glucose complete medium (without fetal bovine serum), cultivated for 12 hours to synchronize the cells in the G0 phase. (2) Dosing: Include HepG2 cells and pri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight/body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.

Description

technical field [0001] The invention relates to the new application of formononetin in medicine, in particular to the application of formononetin in treating non-alcoholic fatty liver. Background technique [0002] Nonalcoholic fatty liver disease, also known as nonalcoholic fatty liver disease (NAFLD), is a clinicopathological syndrome with liver histological changes similar to alcoholic liver disease but without a history of excessive alcohol consumption. Its pathological changes show simple fatty liver, steatohepatitis, fatty liver fibrosis and liver cirrhosis with the progress of the disease course. In recent years, the incidence of NAFLD has shown an obvious upward trend. With the globalization of obesity and its related metabolic syndrome, non-alcoholic fatty liver disease has become an important cause of chronic liver disease in developed countries such as Europe and the United States and in wealthy areas of my country. The prevalence of NAFLD in ordinary adults range...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P1/16
CPCA61K31/352A61P1/16
Inventor 李平彭亮王艳赵海玲
Owner CHINA JAPAN FRIENDSHIP HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap